Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

Strub, 2010, Extracellular and intracellular actions of sphingosine-1-phosphate, Adv Exp Med Biol, 688, 141, 10.1007/978-1-4419-6741-1_10 Maceyka, 2012, Sphingosine-1-phosphate signaling and its role in disease, Trends Cell Biol, 22, 50, 10.1016/j.tcb.2011.09.003 Mutoh, 2012, Insights into the pharmacological relevance of lysophospholipid receptors, Br J Pharmacol, 165, 829, 10.1111/j.1476-5381.2011.01622.x Kanfer, 1966, The metabolism of sphingomyelin. I. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue, J Biol Chem, 241, 1081, 10.1016/S0021-9258(18)96805-5 Tani, 2007, Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space, Cell Signal, 19, 229, 10.1016/j.cellsig.2006.07.001 Kohama, 1998, Molecular cloning and functional characterization of murine sphingosine kinase, J Biol Chem, 273, 23722, 10.1074/jbc.273.37.23722 Liu, 2000, Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform, J Biol Chem, 275, 19513, 10.1074/jbc.M002759200 Chun, 2010, Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis, Clin Neuropharmacol, 33, 91, 10.1097/WNF.0b013e3181cbf825 Noguchi, 2011, Roles for lysophospholipid S1P receptors in multiple sclerosis, Crit Rev Biochem Mol Biol, 46, 2, 10.3109/10409238.2010.522975 Hecht, 1996, Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex, J Cell Biol, 135, 1071, 10.1083/jcb.135.4.1071 An, 1997, Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids, FEBS Lett, 417, 279, 10.1016/S0014-5793(97)01301-X An, 1998, Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid, J Biol Chem, 273, 7906, 10.1074/jbc.273.14.7906 Lee, 1998, Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1, Science, 279, 1552, 10.1126/science.279.5356.1552 Lee, 1998, Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist, J Biol Chem, 273, 22105, 10.1074/jbc.273.34.22105 Zhang, 1999, Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate, Gene, 227, 89, 10.1016/S0378-1119(98)00589-7 Weiner, 1998, Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain, J Comp Neurol, 398, 587, 10.1002/(SICI)1096-9861(19980907)398:4<587::AID-CNE10>3.0.CO;2-5 Dubin, 1999, Lysophosphatidic acid stimulates neurotransmitter-like conductance changes that precede GABA and l-glutamate in early, presumptive cortical neuroblasts, J Neurosci, 19, 1371, 10.1523/JNEUROSCI.19-04-01371.1999 Weiner, 1999, Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid, Proc Natl Acad Sci U S A, 96, 5233, 10.1073/pnas.96.9.5233 Contos, 2000, Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior, Proc Natl Acad Sci U S A, 97, 13384, 10.1073/pnas.97.24.13384 Fukushima, 2000, Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology, Dev Biol, 228, 6, 10.1006/dbio.2000.9930 Ishii, 2000, Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system, Mol Pharmacol, 58, 895, 10.1124/mol.58.5.895 Ishii, 2001, Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3, J Biol Chem, 276, 33697, 10.1074/jbc.M104441200 Weiner, 2001, Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling, J Neurosci, 21, 7069, 10.1523/JNEUROSCI.21-18-07069.2001 Contos, 2002, Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2), Mol Cell Biol, 22, 6921, 10.1128/MCB.22.19.6921-6929.2002 Fukushima, 2002, Dual regulation of actin rearrangement through lysophosphatidic acid receptor in neuroblast cell lines: actin depolymerization by Ca(2+)-alpha-actinin and polymerization by rho, Mol Biol Cell, 13, 2692, 10.1091/mbc.01-09-0465 Fukushima, 2002, Lysophosphatidic acid influences the morphology and motility of young, postmitotic cortical neurons, Mol Cell Neurosci, 20, 271, 10.1006/mcne.2002.1123 McGiffert, 2002, Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1–3) in angiogenesis, FEBS Lett, 531, 103, 10.1016/S0014-5793(02)03404-X Kingsbury, 2003, Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding, Nat Neurosci, 6, 1292, 10.1038/nn1157 Rao, 2003, Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes, Brain Res, 990, 182, 10.1016/S0006-8993(03)03527-3 Inoue, 2004, Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling, Nat Med, 10, 712, 10.1038/nm1060 Rao, 2004, Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes, Int J Dev Neurosci, 22, 131, 10.1016/j.ijdevneu.2004.03.005 Webb, 2004, Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice, J Neuroimmunol, 153, 108, 10.1016/j.jneuroim.2004.04.015 Fukushima, 2007, Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA1-G(i/o) pathway, Neurochem Int, 50, 302, 10.1016/j.neuint.2006.09.008 Herr, 2007, Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2, J Neurosci, 27, 1474, 10.1523/JNEUROSCI.4245-06.2007 Estivill-Torrus, 2008, Absence of LPA1 signaling results in defective cortical development, Cereb Cortex, 18, 938, 10.1093/cercor/bhm132 Choi, 1831, Lysophospholipids and their receptors in the central nervous system, Biochim Biophys Acta, 2013, 20 Lin, 2012, Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain, J Biol Chem, 287, 17608, 10.1074/jbc.M111.330183 Herr, 2011, Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling, Proc Natl Acad Sci U S A, 108, 15444, 10.1073/pnas.1106129108 Yung, 2011, Lysophosphatidic acid signaling may initiate fetal hydrocephalus, Sci Transl Med, 3, 99ra87, 10.1126/scitranslmed.3002095 Welch, 2012, Sphingosine-1-phosphate receptors as emerging targets for treatment of pain, Biochem Pharmacol, 84, 1551, 10.1016/j.bcp.2012.08.010 Liu, 2013, Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke, Int J Neurosci, 123, 163, 10.3109/00207454.2012.749255 Norimatsu, 2012, FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms, Am J Pathol, 180, 1625, 10.1016/j.ajpath.2011.12.012 Tham, 2003, Microglial activation state and lysophospholipid acid receptor expression, Int J Dev Neurosci, 21, 431, 10.1016/j.ijdevneu.2003.09.003 Soliven, 2011, The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators, Neurology, 76, S9, 10.1212/WNL.0b013e31820d9507 Fukushima, 2001, Lysophospholipid receptors, Annu Rev Pharmacol Toxicol, 41, 507, 10.1146/annurev.pharmtox.41.1.507 Siehler, 2002, Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors, Biochim Biophys Acta, 1582, 94, 10.1016/S1388-1981(02)00142-7 Anliker, 2004, Lysophospholipid G protein-coupled receptors, J Biol Chem, 279, 20555, 10.1074/jbc.R400013200 Ishii, 2004, Lysophospholipid receptors: signaling and biology, Annu Rev Biochem, 73, 321, 10.1146/annurev.biochem.73.011303.073731 Novgorodov, 2007, Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration, FASEB J, 21, 1503, 10.1096/fj.06-7420com Mandala, 2002, Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists, Science, 296, 346, 10.1126/science.1070238 Brinkmann, 2002, The immune modulator FTY720 targets sphingosine 1-phosphate receptors, J Biol Chem, 277, 21453, 10.1074/jbc.C200176200 Brinkmann, 2010, Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis, Nat Rev Drug Discov, 9, 883, 10.1038/nrd3248 Chun, 2011, A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya), Discov Med, 12, 213 Cohen, 2011, Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis, Ann Neurol, 69, 759, 10.1002/ana.22426 Matloubian, 2004, Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1, Nature, 427, 355, 10.1038/nature02284 Graler, 2004, The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors, FASEB J, 18, 551, 10.1096/fj.03-0910fje Oo, 2007, Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor, J Biol Chem, 282, 9082, 10.1074/jbc.M610318200 Graeler, 2002, Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells, FASEB J, 16, 1874, 10.1096/fj.02-0548com Mehling, 2008, FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis, Neurology, 71, 1261, 10.1212/01.wnl.0000327609.57688.ea Pappu, 2007, Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate, Science, 316, 295, 10.1126/science.1139221 Foster, 2007, Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis, J Pharmacol Exp Ther, 323, 469, 10.1124/jpet.107.127183 Miron, 2008, Central nervous system-directed effects of FTY720 (fingolimod), J Neurol Sci, 274, 13, 10.1016/j.jns.2008.06.031 Miron, 2010, Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices, Am J Pathol, 176, 2682, 10.2353/ajpath.2010.091234 Choi, 2011, FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation, Proc Natl Acad Sci U S A, 108, 751, 10.1073/pnas.1014154108 Wheeler, 2008, A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis, Brain, 131, 3092, 10.1093/brain/awn190 Kulakowska, 2010, Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis, Neurosci Lett, 477, 149, 10.1016/j.neulet.2010.04.052 Qin, 2010, Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis, J Biol Chem, 285, 14134, 10.1074/jbc.M109.076810 Van Doorn, 2010, Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions, Glia, 58, 1465, 10.1002/glia.21021 Fischer, 2011, Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions, PLoS One, 6, e23905, 10.1371/journal.pone.0023905 Stahl, 1994, The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines, J Neurobiol, 25, 1454, 10.1002/neu.480251111 Bonni, 1997, Regulation of gliogenesis in the central nervous system by the JAK–STAT signaling pathway, Science, 278, 477, 10.1126/science.278.5337.477 Murphy, 1997, Cytokines which signal through the LIF receptor and their actions in the nervous system, Prog Neurobiol, 52, 355, 10.1016/S0301-0082(97)00020-8 Barnabe-Heider, 2005, Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1, Neuron, 48, 253, 10.1016/j.neuron.2005.08.037 Wang, 2008, The astrocyte odyssey, Prog Neurobiol, 86, 342 Pfrieger, 2009, Roles of glial cells in synapse development, Cell Mol Life Sci, 66, 2037, 10.1007/s00018-009-0005-7 Sofroniew, 2010, Astrocytes: biology and pathology, Acta Neuropathol, 119, 7, 10.1007/s00401-009-0619-8 Allaman, 2011, Astrocyte-neuron metabolic relationships: for better and for worse, Trends Neurosci, 34, 76, 10.1016/j.tins.2010.12.001 Molofsky, 2012, Astrocytes and disease: a neurodevelopmental perspective, Genes Dev, 26, 891, 10.1101/gad.188326.112 Miljkovic, 2011, Astrocytes in the tempest of multiple sclerosis, FEBS Lett, 585, 3781, 10.1016/j.febslet.2011.03.047 Moore, 2011, How factors secreted from astrocytes impact myelin repair, J Neurosci Res, 89, 13, 10.1002/jnr.22482 Luo, 2008, Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease, J Neuroinflammation, 5, 6, 10.1186/1742-2094-5-6 Pebay, 2001, Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades, Eur J Neurosci, 13, 2067, 10.1046/j.0953-816x.2001.01585.x Anelli, 2005, Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes, J Neurochem, 92, 1204, 10.1111/j.1471-4159.2004.02955.x Sorensen, 2003, Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes, Mol Pharmacol, 64, 1199, 10.1124/mol.64.5.1199 Wu, 2008, Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease, Hum Mol Genet, 17, 2257, 10.1093/hmg/ddn126 Mullershausen, 2007, Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors, J Neurochem, 102, 1151, 10.1111/j.1471-4159.2007.04629.x Osinde, 2007, Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors, Neuropharmacology, 52, 1210, 10.1016/j.neuropharm.2006.11.010 Miller, 2007, Dissecting demyelination, Nat Neurosci, 10, 1351, 10.1038/nn1995 Terai, 2003, Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS, Neuroscience, 116, 1053, 10.1016/S0306-4522(02)00791-1 Yu, 2004, Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes, Glia, 45, 17, 10.1002/glia.10297 Jaillard, 2005, Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival, J Neurosci, 25, 1459, 10.1523/JNEUROSCI.4645-04.2005 Jung, 2007, Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells, Glia, 55, 1656, 10.1002/glia.20576 Miron, 2008, Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod, Am J Pathol, 173, 1143, 10.2353/ajpath.2008.080478 Miron, 2008, FTY720 modulates human oligodendrocyte progenitor process extension and survival, Ann Neurol, 63, 61, 10.1002/ana.21227 Coelho, 2007, The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors, J Pharmacol Exp Ther, 323, 626, 10.1124/jpet.107.123927 Harada, 2004, Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells, J Neurochem, 88, 1026, 10.1046/j.1471-4159.2003.02219.x Kajimoto, 2007, Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons, Mol Cell Biol, 27, 3429, 10.1128/MCB.01465-06 Mizugishi, 2005, Essential role for sphingosine kinases in neural and vascular development, Mol Cell Biol, 25, 11113, 10.1128/MCB.25.24.11113-11121.2005 MacLennan, 2001, An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability, Eur J Neurosci, 14, 203, 10.1046/j.0953-816x.2001.01634.x Kono, 2007, Deafness and stria vascularis defects in S1P2 receptor-null mice, J Biol Chem, 282, 10690, 10.1074/jbc.M700370200 Ishii, 2002, Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3, J Biol Chem, 277, 25152, 10.1074/jbc.M200137200 Akahoshi, 2011, Frequent spontaneous seizures followed by spatial working memory/anxiety deficits in mice lacking sphingosine 1-phosphate receptor 2, Epilepsy Behav, 22, 659, 10.1016/j.yebeh.2011.09.002 Edsall, 1997, Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation, J Neurosci, 17, 6952, 10.1523/JNEUROSCI.17-18-06952.1997 Toman, 2004, Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension, J Cell Biol, 166, 381, 10.1083/jcb.200402016 Zhang, 2006, Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons, J Physiol, 575, 101, 10.1113/jphysiol.2006.111575 Di Menna, 2013, Fingolimod protects cultured cortical neurons against excitotoxic death, Pharmacol Res, 67, 1, 10.1016/j.phrs.2012.10.004 Rau, 2011, Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis, Am J Pathol, 178, 1770, 10.1016/j.ajpath.2011.01.003 Rossi, 2012, Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis, Br J Pharmacol, 165, 861, 10.1111/j.1476-5381.2011.01579.x Gao, 2011, Animal models of MS reveal multiple roles of microglia in disease pathogenesis, Neurol Res Int, 2011, 383087, 10.1155/2011/383087 Adams, 2007, The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease, J Exp Med, 204, 571, 10.1084/jem.20061931 Nayak, 2010, Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia, Neuroscience, 166, 132, 10.1016/j.neuroscience.2009.12.020 Durafourt, 2011, Differential responses of human microglia and blood-derived myeloid cells to FTY720, J Neuroimmunol, 230, 10, 10.1016/j.jneuroim.2010.08.006 Yoshino, 2011, Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2, Cell Mol Neurobiol, 31, 1009, 10.1007/s10571-011-9698-x Zhang, 2007, FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury, J Cell Mol Med, 11, 307, 10.1111/j.1582-4934.2007.00019.x Czech, 2009, The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia, Biochem Biophys Res Commun, 389, 251, 10.1016/j.bbrc.2009.08.142 Jackson, 2011, Fingolimod modulates microglial activation to augment markers of remyelination, J Neuroinflammation, 8, 76, 10.1186/1742-2094-8-76 Comabella, 2010, Targeting dendritic cells to treat multiple sclerosis, Nat Rev Neurol, 6, 499, 10.1038/nrneurol.2010.112 Zozulya, 2010, The role of dendritic cells in CNS autoimmunity, J Mol Med (Berl), 88, 535, 10.1007/s00109-010-0607-4 Galicia-Rosas, 2012, A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner, J Immunol, 189, 3700, 10.4049/jimmunol.1102261 Stasiolek, 2006, Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis, Brain, 129, 1293, 10.1093/brain/awl043 Lan, 2005, The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo, Am J Transplant, 5, 2649, 10.1111/j.1600-6143.2005.01085.x Gao, 2009, Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-beta, Blood, 114, 2623, 10.1182/blood-2008-10-183301 Correale, 2007, The blood–brain-barrier in multiple sclerosis: functional roles and therapeutic targeting, Autoimmunity, 40, 148, 10.1080/08916930601183522 Lee, 1999, Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate, Cell, 99, 301, 10.1016/S0092-8674(00)81661-X Zhu, 2010, Protein S controls hypoxic/ischemic blood–brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor, Blood, 115, 4963, 10.1182/blood-2010-01-262386 Sanchez, 2003, Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability, J Biol Chem, 278, 47281, 10.1074/jbc.M306896200 Peng, 2004, Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury, Am J Respir Crit Care Med, 169, 1245, 10.1164/rccm.200309-1258OC Dudek, 2007, Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor, Cell Signal, 19, 1754, 10.1016/j.cellsig.2007.03.011 Correale, 2009, Cellular elements of the blood–brain barrier, Neurochem Res, 34, 2067, 10.1007/s11064-009-0081-y Cuzner, 1999, Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system, J Neuroimmunol, 94, 1, 10.1016/S0165-5728(98)00241-0 Waubant, 1999, Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis, Neurology, 53, 1397, 10.1212/WNL.53.7.1397 Foster, 2009, FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood–brain-barrier damage, Brain Pathol, 19, 254, 10.1111/j.1750-3639.2008.00182.x Al-Izki, 2011, Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis, Mult Scler, 17, 939, 10.1177/1352458511400476 Balatoni, 2007, FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis, Brain Res Bull, 74, 307, 10.1016/j.brainresbull.2007.06.023 Kataoka, 2005, FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration, Cell Mol Immunol, 2, 439 Papadopoulos, 2010, FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses, J Neurosci Res, 88, 346, 10.1002/jnr.22196 Hu, 2011, Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo, Mol Cell Neurosci, 48, 72, 10.1016/j.mcn.2011.06.007 Kim, 2011, Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model, FASEB J, 25, 1509, 10.1096/fj.10-173203 Anthony, 2009, Oral fingolimod (FTY720) therapy reduces blood–brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis, Mult Scler, 15, S275 Anthony, 2010, Fingolimod (FTY720) therapy reduces demyelination and microglial activation in a focal DTH model of multiple sclerosis during the remission phase, Mult Scler, 16, S283 Deogracias, 2012, Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome, Proc Natl Acad Sci U S A, 109, 14230, 10.1073/pnas.1206093109 Sheridan, 2012, S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures, Glia, 60, 382, 10.1002/glia.22272 Kipp, 2012, FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination, Mult Scler, 18, 258, 10.1177/1352458512438723 US Food and Drug Administration, 2010 European Medicines Agency, 2011 Cohen, 2010, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, 362, 402, 10.1056/NEJMoa0907839 Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 362, 387, 10.1056/NEJMoa0909494 Shirani, 2012, Association between use of interferon beta and progression of disability in patients with relapsing–remitting multiple sclerosis, JAMA, 308, 247, 10.1001/jama.2012.7625 Barkhof, 2009, Imaging outcomes for neuroprotection and repair in multiple sclerosis trials, Nat Rev Neurol, 5, 256, 10.1038/nrneurol.2009.41 Bermel, 2006, The measurement and clinical relevance of brain atrophy in multiple sclerosis, Lancet Neurol, 5, 158, 10.1016/S1474-4422(06)70349-0 Simon, 2006, Brain atrophy in multiple sclerosis: what we know and would like to know, Mult Scler, 12, 679, 10.1177/1352458506070823 Radue, 2012, Impact of fingolimod therapy on MRI outcomes in patients with multiple sclerosis, Arch Neurol, 69, 1259, 10.1001/archneurol.2012.1051 Zivadinov, 2008, Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis, Neurology, 71, 136, 10.1212/01.wnl.0000316810.01120.05 Miller, 2007, Primary-progressive multiple sclerosis, Lancet Neurol, 6, 903, 10.1016/S1474-4422(07)70243-0 ClinicalTrials.gov, 2011 Kim, 2009, Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy, J Neuroimmunol, 214, 93, 10.1016/j.jneuroim.2009.07.006 Zhang, 2008, FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves, Exp Neurol, 210, 681, 10.1016/j.expneurol.2007.12.025 Commodaro, 2010, Evaluation of experimental autoimmune uveitis in mice treated with FTY720, Invest Ophthalmol Vis Sci, 51, 2568, 10.1167/iovs.09-4769 Maki, 2005, Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720, Transplantation, 79, 1051, 10.1097/01.TP.0000161220.87548.EE Popovic, 2004, The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat, Pediatr Diabetes, 5, 3, 10.1111/j.1399-543X.2004.00036.x Huang, 2012, Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice, Int J Immunopathol Pharmacol, 25, 397, 10.1177/039463201202500209 Kitano, 2006, Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression, Arthritis Rheum, 54, 742, 10.1002/art.21668 Takeshita, 2012, Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator of NF-kappaB ligand (RANKL) expression in rheumatoid arthritis, Biochem Biophys Res Commun, 419, 154, 10.1016/j.bbrc.2012.01.103 Nagai, 2007, Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons, Nat Neurosci, 10, 615, 10.1038/nn1876 Gergely, 2012, The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies, Br J Pharmacol, 167, 1035, 10.1111/j.1476-5381.2012.02061.x Ohno, 2010, The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic–pharmacodynamic modeling, Biopharm Drug Dispos, 31, 396, 10.1002/bdd.719 Piali, 2011, The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation, J Pharmacol Exp Ther, 337, 547, 10.1124/jpet.110.176487 Moberly, 2012, Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients, J Neuroimmunol, 246, 100, 10.1016/j.jneuroim.2012.03.007 Actelion Novartis Vollmer TL, Selmaj K, Bar-Or A, Zipp F. A double-blind, placebo-controlled, phase 2, 26-week DreaMS trial of selective S1P recptor agonist ONO-4641 in patients with relapsing–remitting multiple sclerosis. Presented at the 64th Annual Meeting of the American Academy of Neurology New Orleans 201; 2013. Antel, 2008, Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies, Clin Neurol Neurosurg, 110, 951, 10.1016/j.clineuro.2008.03.021 Gasperini, 2011, Emerging oral drugs for relapsing–remitting multiple sclerosis, Expert Opin Emerg Drugs, 16, 697, 10.1517/14728214.2011.642861 Gold, 2011, Pathophysiology of multiple sclerosis and the place of teriflunomide, Acta Neurol Scand, 124, 75, 10.1111/j.1600-0404.2010.01444.x Korn, 2004, Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide—mechanisms independent of pyrimidine depletion, J Leukoc Biol, 76, 950, 10.1189/jlb.0504308 Merrill, 2009, Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis, J Neurol, 256, 89, 10.1007/s00415-009-0075-3 Wegner, 2010, Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis, J Neuroimmunol, 227, 133, 10.1016/j.jneuroim.2010.07.009 Bruck, 2011, Insight into the mechanism of laquinimod action, J Neurol Sci, 306, 173, 10.1016/j.jns.2011.02.019 Thone, 2012, Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor, Am J Pathol, 180, 267, 10.1016/j.ajpath.2011.09.037 Linker, 2011, Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway, Brain, 134, 678, 10.1093/brain/awq386 Scannevin, 2012, Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway, J Pharmacol Exp Ther, 341, 274, 10.1124/jpet.111.190132 Aharoni, 2012, Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis, J Neuroimmunol, 251, 14, 10.1016/j.jneuroim.2012.06.005 Ruffini F, Rossi S, Bergamaschi A, Brambilla E, Finardi A, Motta C, et al. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler in press. http://dx.doi.org/10.1177/1352458512469698. Bruck, 2012, Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination, Acta Neuropathol, 124, 411, 10.1007/s00401-012-1009-1 Wilms, 2010, Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation, J Neuroinflammation, 7, 30, 10.1186/1742-2094-7-30 Zhao, 2007, Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury, J Neurosci, 27, 10240, 10.1523/JNEUROSCI.1683-07.2007 Hubbs, 2007, Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2, Am J Pathol, 170, 2068, 10.2353/ajpath.2007.060898 Nicholas, 2011, Development of oral immunomodulatory agents in the management of multiple sclerosis, Drug Des Devel Ther, 5, 255, 10.2147/DDDT.S10498 Linker, 2008, Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies, Expert Rev Neurother, 8, 1683, 10.1586/14737175.8.11.1683